ライフサイエンスコーパス: neutralizing antibody

1 imately 11% of sera, which had low levels of neutralizing antibody.

2 nalysis of the viral fusogen together with a neutralizing antibody.

3 an AMPA receptor antagonist or an anti-BDNF neutralizing antibody.

4 , there was no difference in the presence of neutralizing antibodies.

5 ain reaction) and had >=4-fold rise in serum-neutralizing antibodies.

6 ry into host cells and is the main target of neutralizing antibodies.

7 and receptor binding domain) are targets for neutralizing antibodies.

8 he complexes formed are important targets of neutralizing antibodies.

9 thereby contribute to the failure to produce neutralizing antibodies.

10 inant of host range and a dominant target of neutralizing antibodies.

11 inferred germline sequences, to HIV broadly neutralizing antibodies.

12 , CPO RSVs induced lower levels of serum RSV-neutralizing antibodies.

13 approaches for passive delivery of anti-HIV neutralizing antibodies.

14 specific antigenic sites from recognition by neutralizing antibodies.

15 eroreactivity to both RBD and S2 that lacked neutralizing antibodies.

16 alization screening resulted in 268 in vitro neutralizing antibodies.

17 of vascular endothelial growth factor (VEGF)-neutralizing antibodies.

18 ibodies, and decreased the binding of poorly neutralizing antibodies.

19 versified, impeding efforts to isolate cross-neutralizing antibodies.

20 ion resulted in generation of high levels of neutralizing antibodies.

21 r B and T follicular helper cells and plasma neutralizing antibodies.

22 1:1000, of whom 12 had positive results for neutralizing antibodies.

23 contains epitopes for at least four broadly neutralizing antibodies.

24 proteins and the induction of high levels of neutralizing antibodies.

25 cination serum samples were tested for polio-neutralizing antibodies.

26 f high concentrations of SARS-CoV-2-specific neutralizing antibodies.

27 t has not previously emerged as a target for neutralizing antibodies.

28 anti RSV-F immunoglobin (Ig) G, and ChAd155 neutralizing antibodies.

29 cellular immune responses, including potent neutralizing antibodies.

30 , including 10 epitopes likely recognized by neutralizing antibodies.

31 coprotein B (gB) serves as a major target of neutralizing antibodies.

32 of vaccines designed to induce production of neutralizing antibodies.

33 ple HVD/capsid mutants induce high levels of neutralizing antibodies.

34 s as a target for some highly potent broadly neutralizing antibodies.

35 2 spike glycoprotein, the primary target for neutralizing antibodies.

36 after vaccinations was tested for poliovirus-neutralizing antibodies.

37 induced a significant increase in serum RSV-neutralizing antibodies.

38 efforts to design vaccines to induce broadly neutralizing antibodies.

39 haracterized by a fast rise in serum IgG and neutralizing antibodies.

40 Representative neutralizing antibodies 38-1-10A and 38-3-11A both confe

41 lls from natural controllers mainly produced neutralizing antibodies able to cross-react with several

42 ose-dependent gB-binding and cytomegalovirus-neutralizing antibodies (Abs).

43 oral immune response to natural infection is neutralizing antibodies (Abs).

44 newborns or as adults as they produce virus-neutralizing antibodies (Abs).

45 SARS-CoV-2-Nluc can be used to measure neutralizing antibody activity in patient sera within 5

46 s in mice, and mice were given injections of neutralizing antibodies against chemokines, antagonists,

47 ulating factor (G-CSF) and administration of neutralizing antibodies against G-CSF only partially res

48 The vaccine elicitation of broadly neutralizing antibodies against HIV-1 is a long-sought g

49 posed to restrict the development of broadly neutralizing antibodies against HIV-1, but this has not

50 tective in several animal models and induces neutralizing antibodies against protective antigen (PA),

51 imal somatic mutation is needed for potently neutralizing antibodies against SARS-CoV-2.

52 present the potential for the development of neutralizing antibodies against the C-terminal motif of

53 C-SIV regimen in inducing binding and tier 1 neutralizing antibodies against the gp120.

54 noglobulin preparations that need to contain neutralizing antibodies against the pathogens in their e

55 late of such countermeasures is the level of neutralizing antibodies against the SARS-CoV-2 spike pro

56 Animal studies suggest that while neutralizing antibodies against the viral spike protein

57 Furthermore, treating with neutralizing antibodies against TNF-alpha and IFN-gamma

58 nscription in neural progenitor cells, and a neutralizing antibody against CNTF reduced the astrogeni

59 Cetuximab, a monoclonal neutralizing antibody against EGFR, blocks HIV-associate

60 These neutralizing antibodies also function as a main defense

61 as described the high prevalence of anti-AAV neutralizing antibodies among domestic cats in Switzerla

62 otiter plates resulted in 22 unique in vitro neutralizing antibodies and a panning in solution combin

63 including high titers of binding, as well as neutralizing antibodies and ADCC responses.

64 Serum RSV-neutralizing antibodies and anti-RSV fusion immunoglobul

65 The vaccine was tolerated, with induction of neutralizing antibodies and antigen-specific T cells aga

66 ted reactogenicity; we measured IgG binding, neutralizing antibodies and cellular immune responses to

67 In addition, HCV-specific neutralizing antibodies and CXCL13 levels were analyzed.

68 Vaccination induced production of HBV-neutralizing antibodies and increased numbers and functi

69 s on the Spike protein, as it is targeted by neutralizing antibodies and plays a key role in viral en

70 ies in mice found these epitopes induce EBOV-neutralizing antibodies and protect against lethal EBOV

71 erse genetics and evaluated the induction of neutralizing antibodies and protection by rAPMV3 and rND

72 tiviral responses together with induction of neutralizing antibodies and T cell responses.

73 Prefusion SARS-CoV-2 S is the main target of neutralizing antibodies and the focus of vaccine design.

74 ere accompanied by a decline of HCV-specific neutralizing antibodies and the germinal center activity

75 IV-1 envelope protein (Env) is the target of neutralizing antibodies and the template for vaccine imm

76 protein B of HCMV is an important target for neutralizing antibodies and, hence, is often included as

77 recombinant viruses elicited high levels of neutralizing antibody and provided complete protection a

78 lpha, we examined the effects of a TNF-alpha neutralizing antibody and recombinant TNF-alpha soluble

79 ower anti-RSV neutralizing antibodies, where neutralizing antibody (and local IgA) may be a correlate

80 rms can differentially shield the virus from neutralizing antibodies, and (iii) effects of gO polymor

81 ed or maintained the binding of most broadly neutralizing antibodies, and decreased the binding of po

82 city by enzyme-linked immunospot, functional neutralizing antibodies, anti RSV-F immunoglobin (Ig) G,

83 Although virus-neutralizing antibodies are likely to protect, antibodie

84 V-2 S variants that resist commonly elicited neutralizing antibodies are now present at low frequenci

85 Our results demonstrate that SARS-CoV-2-neutralizing antibodies are readily generated from a div

86 We conclude that neutralizing antibodies are stably produced for at least

87 Using a neutralizing antibody assay, we determined that EBV uses

88 Here, using a neutralizing-antibody assay, we found that viral gp350 a

89 suggest that 1 in 5 17D vaccinees will lack neutralizing antibodies at ~10 years postvaccination, an

90 hermore, monotherapy with the potent broadly neutralizing antibody Bc1.187 suppressed viremia in vivo

91 ingle subcutaneous administration of broadly neutralizing antibody (bNAb) 10-1074 conferred durable p

92 g and >100-fold more potent than the broadly neutralizing antibody (bNAb) 3BNC117, with >12,000-fold

93 Abs.IMPORTANCE The efficacy of HIV-1 broadly neutralizing antibody (bnAb) therapies may be compromise

94 cacy of two vaccine candidates and a broadly neutralizing antibody (bNAb) to prevent HIV-1 infection

95 over whether passive infusion of the broadly neutralizing antibody (bNAb) VRC01 can protect against H

96 1 vaccine development aims to elicit broadly neutralizing antibodies (bnAbs) against diverse viral st

97 Broadly neutralizing antibodies (bnAbs) against HIV-1 provide cr

98 on of HIV-1- infected humans develop broadly neutralizing antibodies (bNAbs) against HIV-1 that prote

99 ing of viral infection by a class of broadly neutralizing antibodies (bnAbs) against human immunodefi

100 imers) present multiple epitopes for broadly neutralizing antibodies (bNAbs) and their germline precu

101 IP trimers retained their binding to broadly neutralizing antibodies (bNAbs) and to their unmutated c

102 Broadly neutralizing antibodies (bNAbs) are typically isolated b

103 HIV broadly neutralizing antibodies (bnAbs) can suppress viremia and

104 Broadly neutralizing antibodies (bnAbs) develop in a subset of H

105 In clinical trials, HIV-1 broadly neutralizing antibodies (bnAbs) effectively lower plasma

106 Broadly neutralizing antibodies (bNAbs) have been developed in t

107 Eliciting protective titers of HIV-1 broadly neutralizing antibodies (bnAbs) is a goal of HIV-1 vacci

108 The induction of broadly neutralizing antibodies (bNAbs) is a major goal in vacci

109 complexes with front layer-specific broadly neutralizing antibodies (bNAbs) isolated from HCV-infect

110 de of recognition like that of human broadly neutralizing antibodies (bNAbs) PGT145 and PCT64-35S.

111 Potent broadly neutralizing antibodies (bNAbs) represent a potential al

112 Broadly neutralizing antibodies (bNAbs) represent a promising ap

113 C virus (HCV) is the major target of broadly neutralizing antibodies (bNAbs) that are critical for th

114 ndividuals produced shared clones of broadly neutralizing antibodies (bNAbs) that targeted 3 non-over

115 Understanding how broadly neutralizing antibodies (bnAbs) to influenza hemagglutin

116 s for development of novel vaccines, broadly neutralizing antibodies (bnAbs), and therapeutics.

117 iverse strains of the virus-known as broadly neutralizing antibodies (bnAbs)-could protect against hi

118 ve human VRC01-class B cells and HIV broadly neutralizing antibodies (bnAbs).

119 is preferentially recognized by many broadly neutralizing antibodies (bNAbs).

120 ay be a key aspect in the development of HIV neutralizing antibody breadth.

121 ormer mechanism suggests the need to enhance neutralizing antibody breadth; the latter suggests the n

122 ard an HIV vaccine focus on inducing broadly neutralizing antibodies, but eliciting both neutralizing

123 xpressing HA protein induced higher level of neutralizing antibodies compared to that of rNDV express

124 pose a serious concern to global health, and neutralizing antibodies constitute a promising area of a

125 Enterovirus 71 (EV71)-neutralizing antibodies correlate with protection and ha

126 Titres of vaccine-elicited neutralizing antibodies correlated with protective effic

127 r blocking relevant scavenger receptors with neutralizing antibodies could, therefore, be of value in

128 ly, inhibition of IL-9 or IL-17 cytokines by neutralizing antibodies decreased EMT and slowed lung ca

129 cipients and infants infected in utero Virus-neutralizing antibodies defined in vitro have been propo

130 nse prior to Env trimer immunization elicits neutralizing antibody development and production of anti

131 We hypothesized that autologous neutralizing antibodies directed at the HIV-1 envelope (

132 re also important for viral sensitization to neutralizing antibodies, directly linking the antiviral

133 A large proportion of the non-neutralizing antibodies display high levels of somatic h

134 We find that neutralizing antibody does not prevent the spread of the

135 ich to understand interactions between S and neutralizing antibodies during infection or vaccination.

136 by DeltagD-2 provide greater protection than neutralizing antibodies elicited by rgD-2 against primar

137 classify the antibodies into categories: (1) neutralizing antibodies encoded by the VH3-53 gene segme

138 results provide structural insight as to how neutralizing antibody engagement of CHIKV inhibits diffe

139 Treatment with the EpCAM neutralizing antibody, EpAb2-6, inhibited AKT and FOXO3a

140 velope (E) protein is the dominant target of neutralizing antibodies for dengue virus (DENV) and yell

141 the biodistribution, blood circulation time, neutralizing antibody formation, and targeted delivery a

142 Cao et al. identify thousands of SARS-CoV-2 neutralizing antibodies from convalescent donors.

143 Therefore, the presence of neutralizing antibodies from prior infection was signifi

144 expression, whereas cycloheximide and a TLR3-neutralizing antibody had no effect.

145 are capable of inducing strain-transcendent neutralizing antibodies has renewed enthusiasm for the p

146 Indeed, treatment with IL-17RB-neutralizing antibody has a synergistic effect in combin

147 Neutralizing antibodies have become an important tool in

148 Although neutralizing antibodies have been proposed as a potentia

149 ed the technology to the production of human neutralizing antibodies in a transchromosomic (Tc) bovin

150 for the presence of anti SARS-CoV-2 specific neutralizing antibodies in convalescent patient serum.

151 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens an

152 rofile and induces high levels of SARS-CoV-2 neutralizing antibodies in hamsters (Mesocricetus auratu

153 e CPO RSVs induced lower levels of serum RSV-neutralizing antibodies in hamsters.

154 wed evidence of virus replication but not of neutralizing antibodies in her nasopharyngeal swabs.

155 envelope (E) protein is the major target of neutralizing antibodies in infected hosts and thus repre

156 COV-2 Spike were successfully used to detect neutralizing antibodies in plasma from coronavirus disea

157 rve virus replication in the near absence of neutralizing antibody in this unique mouse model.IMPORTA

158 fferent from those recognized by lower-level neutralizing antibodies induced by monomers.

159 assive immunization treatments using broadly neutralizing antibodies is a promising therapeutic appro

160 gree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear.

161 high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19

162 er therapeutic response without the need for neutralizing antibodies isolated from convalescent patie

163 human noroviruses allows the measurement of neutralizing antibody levels.

164 nt and shape the maturation of a broad HIV-1-neutralizing antibody lineage.

165 is of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate t

166 to receive a single intravenous infusion of neutralizing antibody LY-CoV555 in one of three doses (7

167 -cell entry and is the primary target of the neutralizing antibody-mediated immune response.

168 greatly increased germinal center, antibody, neutralizing antibody, memory and long-lived plasma cell

169 Therapeutic prevention of IL11 activity with neutralizing antibodies mirrored the effects of genetic

170 y confer neurovirulence or escape from virus-neutralizing antibody (nAb) in vivo is unknown.

171 O-NPs) to create a particulate immunogen for neutralizing antibody (NAb) induction.

172 dinal antibody responses were identified for neutralizing antibody (Nab) potential, and differences i

173 the AMC009 trimers did not induce autologous neutralizing antibody (NAb) responses efficiently while

174 IgG3 bAb responses, IgG bAb breadth scores, neutralizing antibody (nAb) responses, antibody-dependen

175 nts during the 2017-2018 season to determine neutralizing antibody (nAb) titers and for influenza vir

176 However, knowledge regarding neutralizing antibody (NAb) titers in donor plasma and t

177 126 plasma samples, 101 (80%) had detectable neutralizing antibody (nAb) titers.

178 To determine whether neutralizing antibodies (nAbs) against CMV pentameric co

179 ile methodology for rapid epitope mapping of neutralizing antibodies (NAbs) against HIV-1 Envelope (E

180 neutralizing antibodies, but eliciting both neutralizing antibodies (nAbs) and cellular responses ma

181 We isolated autologous neutralizing antibodies (nAbs) and described their struc

182 Analysis of the specificity and kinetics of neutralizing antibodies (nAbs) elicited by SARS-CoV-2 in

183 advances in the research and development of neutralizing antibodies (nAbs) for the prevention and tr

184 ns are vaccine components intended to induce neutralizing antibodies (NAbs) that prevent cells from i

185 We isolated potent neutralizing antibodies (nAbs) to two epitopes on the re

186 t chimeric SOSIP trimers and elicited tier 2 neutralizing antibodies of higher potency than noncomple

187 zation assay-geometric mean titers (GMTs) of neutralizing antibodies of the vaccine group (46; 95% CI

188 better than did TB or TR in the presence of neutralizing antibodies on both cell types, indicating t

189 Geometric mean titres of SARS-CoV-2 serum-neutralizing antibodies on day 43 were 0.7-fold (1-mug d

190 ypes of studies, such as characterization of neutralizing antibodies or development of fusion-inhibit

191 NF2-null cells treated with an ERBB3-neutralizing antibody partially downregulated mTOR pathw

192 able regions 1 and 2 (V1V2)-targeted broadly neutralizing antibody PG9 to block productive infection,

193 etermined the crystal structure of CR3022, a neutralizing antibody previously isolated from a convale

194 We demonstrate that neutralizing antibodies produced in rabbits and nonhuman

195 of ChAd-SARS-CoV-2-S induces high levels of neutralizing antibodies, promotes systemic and mucosal i

196 escribed REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987 and REGN10933) that t

197 Spike RBD and S2 and neutralizing antibodies remained detectable through 5-7

198 mation, preferentially recognized by broadly neutralizing antibodies, remains unknown.

199 precursor B cell receptors of HIV-1 broadly neutralizing antibodies requires specifically designed i

200 Based on these data, a neutralizing antibody response above 3.02 log(10) EC50 w

201 not cause diarrhea in animals and elicits a neutralizing antibody response in virus-infected animals

202 We show that the kinetics of the neutralizing antibody response is typical of an acute vi

203 ically, primary infection generates a robust neutralizing antibody response that mediates viral contr

204 er, we document that cats developed a robust neutralizing antibody response that prevented reinfectio

205 PIZV elicited a dose-dependent neutralizing antibody response which is protective for a

206 on but do seroconvert and mount an antiviral neutralizing antibody response.

207 n G (IgG) antibody responses and mumps virus-neutralizing antibody responses (based on the focus-redu

208 its immunized with SOSIP-NVP elicited strong neutralizing antibody responses against HIV-1.

209 n should be considered for inducing strongly neutralizing antibody responses against SARS-CoV-2.

210 ARS-CoV-2 spike protein elicited binding and neutralizing antibody responses and protected against SA

211 The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or

212 Additionally, we detect robust and sustained neutralizing antibody responses and the antibodies elici

213 therapeutics and are a major contributor to neutralizing antibody responses elicited by infection.

214 Here we show that mRNA-1273 induces potent neutralizing antibody responses to both wild-type (D614)

215 Molecular understanding of neutralizing antibody responses to severe acute respirat

216 Neutralizing antibody responses were detectable in 36% b

217 IgA, IgM, and IgG and neutralizing antibody responses were quantified in serum

218 obulin (Ig)M, IgA, IgG) in >95% of cases and neutralizing antibody responses when sampled beyond 8 d

219 als who developed unusually broad and potent neutralizing antibody responses, might serve as blueprin

220 To gain a deeper understanding of cross-neutralizing antibody responses, we mined the memory B c

221 )) and CD8(+) T-cell and ZIKV-specific serum-neutralizing antibody responses.

222 at can potentially hinder induction of broad neutralizing antibody responses.

223 of ZIKV resulted in the generation of serum-neutralizing antibody responses.

224 e than 90% of seroconverters make detectable neutralizing antibody responses.

225 pitopes of protein antigens for induction of neutralizing antibody responses.

226 Binding- and neutralizing-antibody responses appeared to be similar t

227 candidates capable of eliciting potent ZIKV-neutralizing antibodies (reviewed in refs.

228 Neutralizing antibodies rose in tandem with immunoglobul

229 rization of two ultrapotent SARS-CoV-2 human neutralizing antibodies (S2E12 and S2M11) that protect h

230 y the FDA in 2019, is a humanized sclerostin-neutralizing antibody (Scl-Ab) indicated in postmenopaus

231 ne variant that displayed a >=4-fold reduced neutralizing antibody sensitivity against at least one M

232 We created 8 novel CARs using anti-CMV neutralizing antibody sequences, which were transduced v

233 Neutralizing antibody seroresponses were observed in 71%

234 The best in vitro neutralizing antibody showed an estimated relative poten

235 Broadly neutralizing antibodies similar to the human V(H)1-69 cl

236 e HMPV entry was fully inhibited by 54G10, a neutralizing antibody, spread was only modestly reduced,

237 Furthermore, clinically approved PCSK9-neutralizing antibodies synergize with anti-PD1 therapy

238 ical to the infection cycle of HIV, and most neutralizing antibodies target the high-mannose glycans

239 Neutralizing antibodies that act by sterically blocking

240 ecific plasma cells are capable of producing neutralizing antibodies that are essential for clearance

241 nd bind only to 'up' RBDs; (2) ACE2-blocking neutralizing antibodies that bind both up and 'down' RBD

242 own' RBDs and can contact adjacent RBDs; (3) neutralizing antibodies that bind outside the ACE2 site

243 l of NoV, and recent studies have identified neutralizing antibodies that bind the capsid protein VP1

244 us is the induction of cross-reactive poorly neutralizing antibodies that can cause antibody-dependen

245 4-induced (CD4i) exposure of epitopes of non-neutralizing antibodies that can potentially hinder indu

246 valuable insights into epitopes targeted by neutralizing antibodies that could be potent targets for

247 cific and flavivirus cross-reactive potently neutralizing antibodies that have been mapped to quatern

248 we show that older individuals make broadly neutralizing antibodies that have no hemagglutination-in

249 e were able to identify target structures of neutralizing antibodies that potently block gB-induced m

250 mary ZIKV infection generates high titers of neutralizing antibodies that protect from detectable pla

251 e, a goal of HCV vaccine design is to induce neutralizing antibodies that target conserved epitopes.

252 HPV vaccines generate functional (neutralizing) antibodies that target the virus particles

253 vaccine strategies focus on the induction of neutralizing antibodies, there is substantial evidence t

254 t increase in the serum RSV-plaque-reduction neutralizing antibody titer (RSV-PRNT).

255 c (geometric mean serum RSV plaque-reduction neutralizing antibody titer, 1:64).

256 sed as percentage of those with rabies virus neutralizing antibodies titers >= 0.5 IU/mL on day 14.

257 accinees had >=4-fold increases in serum RSV-neutralizing antibody titers after the RSV season withou

258 ral and cellular immune responses, including neutralizing antibody titers at levels comparable to tho

259 We assessed neutralizing antibody titers for the four dengue serotyp

260 (IgG), immunoglobulin-M (IgM), and in vitro neutralizing antibody titers in COVID-19 patients.

261 All subjects achieved accepted neutralizing antibody titers of >=0.5 IU/mL following th

262 cline, low to undetectable viremia, and high neutralizing antibody titers throughout the disease cour

263 Postvaccination neutralizing antibody titers to 3c2.A and 3c2.A2 were hi

264 Postvaccination neutralizing antibody titers to H1N1 were similar among

265 The 100-mug dose induced higher binding- and neutralizing-antibody titers than the 25-mug dose, which

266 infective dose (ID(50) > 10,000) maintained neutralizing antibody titres >1,000 at >60 d POS, some w

267 ort, there was also a significant decline in neutralizing antibody titres against ZIKV, but not again

268 t >60 d POS, some with lower peak ID(50) had neutralizing antibody titres approaching baseline within

269 of an acute viral infection, with declining neutralizing antibody titres observed after an initial p

270 A similar decline in neutralizing antibody titres was observed in a cohort of

271 Neutralizing antibodies to adeno-associated virus (AAV)

272 The neutralizing antibodies to benralizumab may have resulte

273 tion of asthma, which was possibly caused by neutralizing antibodies to benralizumab.

274 ENV)-experienced human elicited potent cross-neutralizing antibodies to both ZIKV and DENV.

275 allenges and produced broadly cross-reactive neutralizing antibodies to H2 influenza viruses.

276 d blood spot (DBS) specimens were tested for neutralizing antibodies to poliovirus types 1, 2, and 3

277 Achieving high levels of neutralizing antibodies to the spike protein of SARS-CoV

278 elevated expression of alpha5 subunit, and a neutralizing antibody to alpha5 subunit reduced adhesion

279 ors; however, this increase was blocked by a neutralizing antibody to integrin alpha(V)beta(5).

280 Continuous central administration of a neutralizing antibody to the IFN-alpha/beta receptor (IF

281 nduce cross-reactive, potentially even cross-neutralizing, antibodies to the new species in humans is

282 imized for eliciting virus-specific strongly neutralizing antibodies upon vaccination.

283 Infusion of the broadly neutralizing antibody VRC01 has been evaluated in indivi

284 TDF and FTC in combination with the broadly neutralizing antibody VRC01-N using a highly reproducibl

285 0) in anti-F IgG over the fold-rise in RSV-A-neutralizing antibodies was 1.01.

286 FGF2 signaling by central injection of FGFR3-neutralizing antibody was able to reverse the diminishme

287 Production of neutralizing antibody was increased by >10-fold while ut

288 To identify SARS-CoV-2-neutralizing antibodies, we analyzed the antibody respon

289 Measles virus neutralizing antibodies were also measured by in vitro p

290 Poliovirus neutralizing antibodies were measured in sera collected

291 Serum toxin A- and B-specific neutralizing antibodies were measured.

292 Cross-neutralizing antibodies were more frequently elicited by

293 However, the neutralizing antibodies were not produced in sufficient

294 onverting enzyme 2 (ACE2) and cross-reacting neutralizing antibody were found to be conserved among t

295 severity in adults were: (1) lower anti-RSV neutralizing antibodies, where neutralizing antibody (an

296 findings suggest that the potency of poorly neutralizing antibodies, which are commonly elicited in

297 djuvant AddaVax, the RBD derivative elicited neutralizing antibodies with an endpoint geometric mean

298 Class 2 contained four neutralizing antibodies with epitopes that bridged RBDs,

299 Co-crystal structures of two IGHV3-53-neutralizing antibodies with RBD, with or without Fab CR

300 zation assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with pati